• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Corrigendum to "A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation" [Eur J Canc 131 (2020) 68-75].

作者信息

Lala Mallika, Li Tommy Ruosi, de Alwis Dinesh P, Sinha Vikram, Mayawala Kapil, Li Mengyao, Yamamoto Noboru, Siu Lillian L, Chartash Elliot, Aboshady Hesham, Jain Lokesh

机构信息

Quantitative Pharmacology and Pharmacometrics; Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ, USA.

Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.

出版信息

Eur J Cancer. 2021 Feb;144:400. doi: 10.1016/j.ejca.2020.12.006. Epub 2021 Jan 4.

DOI:10.1016/j.ejca.2020.12.006
PMID:33414065
Abstract
摘要

相似文献

1
Corrigendum to "A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation" [Eur J Canc 131 (2020) 68-75].《基于建模与模拟评估的帕博利珠单抗用于癌症患者的每六周（Q6W）给药方案》勘误 [《欧洲癌症杂志》131卷（2020年）68 - 75页]
Eur J Cancer. 2021 Feb;144:400. doi: 10.1016/j.ejca.2020.12.006. Epub 2021 Jan 4.
2
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.基于建模和模拟评估的癌症患者每六周一次的帕博利珠单抗给药方案。
Eur J Cancer. 2020 May;131:68-75. doi: 10.1016/j.ejca.2020.02.016. Epub 2020 Apr 15.
3
Letter to the editor: Comments on 'A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation'.致编辑的信：关于“基于建模与模拟评估的癌症患者帕博利珠单抗六周给药方案”的评论
Eur J Cancer. 2020 Oct;138:54-56. doi: 10.1016/j.ejca.2020.07.014. Epub 2020 Aug 24.
4
Corrigendum to 'Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer', [Eur J Canc 51 (2015) 482-488].
Eur J Cancer. 2021 Apr;147:187. doi: 10.1016/j.ejca.2021.01.019. Epub 2021 Feb 18.
5
Corrigendum to "The use of 'added benefit' to determine the price of new anti-cancer drugs in France, 2004-2017" [Eur J Canc 145 (2021) 11-18].
Eur J Cancer. 2021 Jul;152:259-261. doi: 10.1016/j.ejca.2021.04.018. Epub 2021 May 11.
6
Corrigendum to "Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database" [Eur J Canc 125, (January 2020) 153-163].
Eur J Cancer. 2020 Sep;137:288-289. doi: 10.1016/j.ejca.2020.05.006. Epub 2020 Jun 27.
7
Corrigendum to '5-Aza-2'-deoxycytidine potentiates antitumor immune response induced by photodynamic therapy' [the Eur J Canc (2014) 1370-1381].
Eur J Cancer. 2021 Jan;142:150-151. doi: 10.1016/j.ejca.2020.10.001. Epub 2020 Oct 24.
8
Corrigendum to 'Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial' [Eur J Canc 124 (January 2020) 25-36].
Eur J Cancer. 2020 Sep;136:207-208. doi: 10.1016/j.ejca.2020.05.019. Epub 2020 Jul 7.
9
Corrigendum to "Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma" [Eur J Canc 157 (2021) 250-258].《西米普利单抗治疗局部晚期和转移性皮肤鳞状细胞癌的真实世界数据》的勘误 [《欧洲癌症杂志》157卷（2021年）250 - 258页]
Eur J Cancer. 2022 May;166:309-310. doi: 10.1016/j.ejca.2022.02.027. Epub 2022 Mar 24.
10
Corrigendum to "Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia)" [Eur J Canc. vol. 139 November (2020) Pages 149-168].《代表意大利妇产科协会（S.I.G.O.）召开的子宫肉瘤管理意大利共识会议》勘误 [《欧洲癌症杂志》第139卷，2020年11月，第149 - 168页]
Eur J Cancer. 2021 Feb;144:397-398. doi: 10.1016/j.ejca.2020.11.001. Epub 2020 Dec 22.

引用本文的文献

1
Strategies for selecting/switching chemotherapy and supportive care treatments during COVID-19 outbreak.2019冠状病毒病疫情期间选择/更换化疗及支持性治疗的策略。
Cancer Med. 2020 Sep;9(17):6079-6081. doi: 10.1002/cam4.3314. Epub 2020 Jul 20.